• Vaccine Name: Influenza vaccine with NP antigen and Adjuplex+GLA adjuvant
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Type: Subunit vaccine
• Status: Licensed
• Host Species for Licensed Use: Mouse
• Preparation: ADJ, in combination with Toll-like receptor (TLR) 4/9 agonists; (Marinaik et al., 2020)
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Immune Response: An acrylic-acid-based adjuvant (ADJ), in combination with Toll-like receptor (TLR) agonists glucopyranosyl lipid adjuvant (GLA) or CpG, promotes mucosal imprinting but engages distinct transcription programs to drive different degrees of terminal differentiation and disparate polarization of TH1/TC1/TH17/TC17 effector/memory T cells. Combination of ADJ with GLA, but not CpG, dampens T cell receptor (TCR) signaling, mitigates terminal differentiation of effectors, and enhances the development of CD4 and CD8 TRM cells that protect against H1N1 and H5N1 influenza viruses. ADJ, in combination with Toll-like receptor (TLR) 4/9 agonists, elicits unexpectedly potent and functionally diverse CD8 and CD4 T cell responses to a subunit viral protein in the RT. (Marinaik et al., 2020)